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Obesity represents a major challenge to the pharmaceutical community due to the minimal availability 
of anti-obesity drugs and the drawbacks of current weight-loss agents. The study described herein 
presents lupine oil, in two pharmaceutical formulations, as a potential anti-obesity agent via its effect 
on different physiological, biochemical, and hormonal parameters. Rats were divided into two groups; 
one group was continued on a standard commercial rodent diet and served as the non-obese control. 
The other group was fed a high-fat diet for 7 weeks to prepare an obese rat model. Then, the obese 
rats were divided into groups to receive 100 mg/kg of the crude lupine oil or nanoemulsion for 10 or 
20 days. Lupine oil showed a potent body weight-reducing effect and improved insulin resistance. The 
oil altered obesity-induced hyperlipidemia and it enhanced the leptin/adiponectin/AMPK hormonal 
system in epididymal fat, serum, and liver, to which all the above physiological activities could be 
attributed. The nanoemulsion formulation of lupine oil significantly amplified the activity for all the 
above physiological and hormonal parameters when compared to the crude oil formulation. Lupine oil 
nanoemulsion could be used as a potential drug against diet-induced obesity. 
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INTRODUCTION
Obesity is a major health and social problem with 
huge impacts on one’s quality of life. The prevalence 
of obesity is linked with a disturbing increase in 
several diseases, such as diabetes mellitus, metabolic 
syndrome, chronic kidney disease, and many life-
threatening cardiovascular disorders (Sbihi et al., 
2013). The number of obese individuals is increasing, 
and millions of potential patients have been identified 
worldwide (Park, Usher, Foster, 2011). Adipokines, a 
group of hormones principally secreted from fat tissues, 
to modulate insulin sensitivity and fat metabolism 
(Rabe et al., 2008); they are thought to play essential 
roles in obesity and its related syndromes (Chang 
et al., 2010). Among the adipokines, leptin and 
adiponectin are considered the major players in obesity 
metabolism, as they primarily regulate adenosine 
monophosphate (AMP)-activated protein kinase 
(AMPK) activity (Dzamko, Steinberg, 2009). Leptin 
activates many kinases and signal transducers, which 
inhibit orexigenic peptides and activate anorexigenic 
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peptides (Ahima, 2006). Leptin restricts food intake 
and suppresses hypothalamic AMPK activity, while 
adiponectin stimulates hypothalamic AMPK, which 
controls energy expenditure (Stark, Ashley, Andrews, 
2013). Furthermore, leptin decreases glucose, recovers 
insulin resistance, diminishes hyperlipidemia (Havel, 
2002), and stimulates lipolysis through central and 
peripheral pathways involving AMPK (Ahima, 
2006). AMPK switches off pathways of adenosine 
triphosphate (ATP) consumption and switches on the 
ATP production pathways, such as fatty acid oxidation 
and glucose uptake. Moderated AMPK activity in the 
liver, muscle, adipose tissue, and other peripheral tissues 
is a predisposing factor for obesity and diabetes as it 
reduces one’s exercise capacity and glucose tolerance 
(Stark, Ashley, Andrews, 2013). 
Lupine (Lupinus albus), a member of the Fabaceae 
family, is located around the Mediterranean Sea region, 
especially in North Africa and along the Nile River. 
Lupine’s seed contains protein, lipids, fatty acids, amino 
acids, carbohydrates, and some minerals such as copper, 
phosphorus, calcium, and manganese. In addition, the 
plant contains various amounts of vitamin E, vitamin C, 
thiamin, riboflavin, and niacin (Lampart-Szczapa et al., 
2003a). Lupine seeds contain up to 2% of quinolizidine 
alkaloids such, as lupinine and gramine, which are known 
to be toxic to humans and animals; however, repetitive 
soaking in water in room temperature (debittering) 
allows such poisonous alkaloids to be eliminated (El-
Shazly, Ateya, Wink, 2001). Lupine seeds feature many 
proven pharmacological and medicinal activities, such 
as hypoglycemic (Sheweita et al., 2002), hypotensive, 
and diuretic activities (Medhin et al., 1986). Lupine seed 
extract also exhibits anti-bacterial properties due to the 
presence of phenolic compounds (Lampart-Szczapa 
et al., 2003 b). The seed can produce up to 12% of its 
total weight as oil, containing components of different 
saturated and unsaturated fatty acids. The fatty acid 
composition of the lupine seed oil renders oleic acid as 
the most abundant fatty acid (40%–50%), followed by 
linoleic acid (8%–16%), and α-linolenic acid (5%–10%) 
(Sbihi et al., 2013). Although the pharmacological and 
medicinal activities of lupine seeds are well recognized, 
there are few reports that discuss the oil. Lupine oil has 
been used in the development of several cosmetic and 
topical preparations as anti-wrinkle, sunscreen, and 
skin protection agents (Sipsas, 2008). However, there 
is almost no literature discussing the medicinal use 
of lupine oil. The influence of lupine-enriched foods 
on obesity and related cardiovascular diseases is well 
scrutinized; nevertheless, all research attributed this 
activity to the protein and fibrous parts of the seed 
(Belski et al., 2011). The effect of lupine oil on such 
syndromes has never been investigated. 
Emulsions, both oil in water (o/w) or water in oil 
(w/o), exist in pharmaceutical markets to overcome the 
formulation difficulties usually associated with oily 
products, such as bitter taste, moderated solubility, weak 
absorption, and poor bioavailability (Savjani, Gajjar, 
Savjani, 2012). For instance, the absorption of crude fish 
oil was enhanced by 300% via an emulsification process 
(Raatz et al., 2009); yet stability-related obstacles in 
the emulsified products, such as creaming, cracking, 
and phase separation, could represent a great drawback 
during their formulation (Kamba, Itodo, Ogah, 2013). 
Nanoemulsion has recently attracted much attention 
in pharmaceutical research for its capability to reduce 
the drawbacks associated with regular emulsion. 
Nanoemulsion is an emulsion process featuring particle 
sizes <1,000 nm, obtained through two successive 
homogenization processes: primary and secondary. 
The primary homogenization process aims to mix the 
immiscible phases with the aid of an emulsifying agent, 
while the secondary homogenization process decreases 
the size of the emulsion droplet particles to nanoscale 
(Sharma et al., 2013). 
Obesity and its related ailments are increasing 
worldwide, and numerous weight-loss drugs are 
associated with many safety concerns. The aim of 
this study is to propose lupine oil, both crude and 
nanoemulsion formulations, as a natural medication for 
obesity and its related complications by investigating the 




Sunflower oil was purchased from Al-Ahlam 
Company for seed oil production (Jeddah, Saudi 
Arabia). Tween 20 was purchased from Sigma-Aldrich 
Co. (St Louis, MO, USA). Leptin rat enzyme-linked 
immunosorbent assay (ELISA) kit (ab100773) and 
adiponectin rat ELISA kit (ab108784) were obtained 
from Abcam plc (Cambridge, UK). A rat insulin 
ELISA kit (80-INSRT-E01) was purchased from 
ALPCO Diagnostics (Salem, NH, USA). AMPKα1/2 
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(SC-25792), ACRP30, leptin (SC-842), β-actin 
(SC-130656), goat anti-rabbit immunoglobulin (Ig)
G-horseradish peroxidase (HRP) (SC-2030) antibodies, 
luminol reagent (SC-2048), and polyvinylidene fluoride 
(PVDF) membrane (SC-3723) were purchased from 
Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). 
Alanine aminotransferase (ALT), blood glucose, total 
cholesterol, and high-density lipoprotein (HDL)–
cholesterol kits were purchased from United Diagnostic 
Industry (Dammam, KSA). The remaining chemicals 
used were of analytical grade and obtained from a local 
distribution agent in KSA.
Plant materials
The seeds of sweet white lupine (Lupinus albus, 
family Fabaceae) were collected from a local farm 
near Cairo, Egypt in May 2014 when the plant was in 
its flowering and fruiting stage. The whole plant was 
identified by Dr. AH Mohamed, plant taxonomist, 
Egyptian Agricultural Museum, Cairo, Egypt. Voucher 
specimens were deposited in the herbarium of the 
Department of Pharmacognosy, Faculty of Pharmacy, 
Zagazig University, Egypt, under number F352.
Isolation of lupine oil 
Lupine seeds were debittered to remove toxic 
alkaloids according to (Erbas, 2010), as follows: the 
lupine seeds were soaked in water for 12 hours, and 
they were then boiled for 1 hour (a ratio of 1:3 of seeds: 
water [w/v]) to soften the seeds. The boiled seeds were 
debittered by soaking them again in tap water for 48 
hours at room temperature (25 ºC); the debittering water 
was changed every 2 hours. The soaked seeds were 
allowed to dry; they were then powdered using a plant 
grinder (IKA-M20). A total of 250 g of powder were 
extracted using 1 L of n-hexane in a Soxhlet apparatus 
for 6 hours at 70 ºC. The organic solvent was evaporated 
under reduced pressure to obtain the crude oil (9.4% 
yield). The oil samples were kept in a refrigerator at 
4 ºC until further use. Crude lupine oil was diluted using 
sunflower oil to reach the required concentration for 
administration to the animals.
Preparation of the nanoemulsion
Nanoemulsions were formulated with different 
ratios, as detailed in the table below. Crude lupine oil, 
diluted with sunflower oil, was vortexed with Tween 20 
for 10 minutes at 2,000 rpm; then, the aqueous phase 
was added slowly with continuous mixing for an extra 
10 minutes until a milky white emulsion was obtained. 
The second homogenization was performed with a 
homogenizer (IKA-T25; Germany) at 10,000 rpm for 
5 minutes to produce four nanoemulsion formulas with 
different ratios, as outlined in table I. The produced 
nanoemulsions were stored in tightly sealed glass 
containers until further analysis.








Tween 20  
(g)
F1 0.25 1.05 2.70 1
F2 0.25 1.25 2.50 1
F3 0.25 1.45 2.30 1
F4 0.25 1.65 2.10 1
Characterizations of nanoemulsions
Particle size determination
A total of 10 µL of the prepared nanoemulsions 
were diluted with 3 mL of distilled water; their particles 
sizes were determined through a Malvern zetasizer 
(Nanoseries, zs; Malvern Instruments, Malvern, UK).
Viscosity determination
The viscosity of the prepared nanoemulsions was 
determined through a Brookfield viscometer (DV-II 
Pro; USA). The dynamic viscosity measurements were 
determined using spindle No. 64 and 60 rpm at room 
temperature.
Investigation of phase separation 
The prepared nanoemulsions were kept for 3 
months at room temperature; the phase separation was 
investigated and photographically recorded. 
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Animals
Thirty male Sprague–Dawley rats weighing 
(170±25 g) were obtained from the College of Veterinary 
Medicine and Animal Resources, King Faisal University, 
Hofuf, KSA. The rats were kept in standard laboratory 
conditions (23 °C±1 °C) and maintained on a standard 
commercial rodent diet using a 12-hour light/dark cycle 
throughout the accommodation period (1 week). 
In vivo experimental design
All animal experimental procedures and protocols 
were approved by the Animal Research Ethics 
Committee at King Faisal University, and they were 
performed in accordance with the Guidelines for the 
Ethical Conduct for Use of Animals in Research, King 
Faisal University. Rats were divided into two groups 
after acclimating to the facility: one group (n=5) was 
continued on a standard commercial rodent diet and 
served as the non-obese control (NO). The other group 
(n=25) was fed a high-fat diet (HFD; a rodent diet with 
60% of its energy provided from fat; Research Diet, 
New Brunswick, NJ, USA) for 7 weeks to prepare 
the obese animal model. After 7 weeks, the obese rat 
group was divided into five groups: untreated obese 
rats (obese); obese rats that received 100 mg/kg of the 
crude lupine oil diluted in sunflower oil for 10 days (L-
10) or 20 days (L-20); and obese rats that received 100 
mg/kg of the lupine oil in nanoemulsion formulation 
for 10 days (NL-10) or 20 days (NL-20). Untreated 
control obese rats (obese group) have received an 
equal volume of sunflower oil as a vehicle of lupine 
crude oil doses or nanoemulsion formulations. All 
obese rats were fed the HFD during the treatment 
period, and all formulations were administered by 
oral gavage. By the end of each designated time, the 
rats were sacrificed and their blood was collected, 
as were their liver tissues and epididymal fat. The 
serum was separated by centrifugation of the blood at 
3,000 rpm for 10 minutes, and samples were stored at 
temperatures of −20 °C until analysis.
Determination of physiological and 
biochemical parameters
Blood glucose, serum insulin, ALT, total 
cholesterol, and HDL levels were measured by their 
corresponding kits, as mentioned under the chemicals 
and reagents section, and according to manufacturer 
protocols. Food intake by all rats was determined 
according to Jeong et al. (2016), where the food intake 
of the obese group was considered to be 100%, and the 
food intake of the other groups was calculated every 
3 days. The body weight (g) and epididymal fat weight 
(g) of all groups were also determined as biochemical 
parameters.
Hormonal determination
Leptin and adiponectin were determined in serum 
using the kits described under the chemical and reagent 
section and according to manufacturer protocols. Leptin, 
adiponectin, and AMPK expression were determined 
in the epididymal fat by Western blot analysis, as will 
be described. Similarly, AMPK was also determined 
in the liver homogenate by Western blot analysis. The 
blot analysis was performed as described by (Takasawa 
et al., 2008). Briefly, liver or epididymal fat samples 
were homogenized in radioimmunoprecipitation assay 
(RIPA) buffer with a protease inhibitor; the total protein 
extracted from those homogenates was quantified using 
a NanoDrop Lite spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA, USA). Then, 50 µg of the 
total extracted protein was separated by sodium dodecyl 
sulfate (SDS)-polyacrylamide gel electrophoresis 
(PAGE) and blotted onto PVDF membranes. The 
membranes were blocked by incubation in Tris-buffered 
saline (TBS) containing 3% bovine serum albumin and 
0.1% Tween 20 for 1 hour at room temperature. After 
washing with TBS containing 0.1% Tween 20, the 
membranes were incubated with the primary antibodies 
(1:300 dilution) for 2 hours at room temperature, and 
they were then incubated with the secondary antibody 
(goat anti-rabbit HRP-conjugated at a 1:5,000 dilution). 
The chemiluminescence produced from the luminol 
reagent was detected with the LI-COR C-DiGit 
chemiluminescence scanner, and the intensity of the 
bands was analyzed using the scanner software. In 
the epididymal fat experiment, loading uniformity 
was assessed by Ponceau S staining of the membranes 
after blotting given the low expression of β-actin in the 
adipose tissue.
Statistical analysis
Data were expressed as the mean ± standard 
deviation (SD) of at least three independent experiments 
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(n=5). Statistically significant differences between the 
groups were determined by means of one-way analysis 
of variance (ANOVA) followed by Tukey’s multiple 
comparison test using IBM SPSS software (IBM SPSS 
Statistics for Windows (2010), Version 19.0. Armonk, 
NY: IBM Corp). In all cases, probability values of 
P<0.05 were taken as statistically significant.
RESULTS
Crude lupine oil was extracted from the plant seeds 
after a debittering process in which toxic alkaloids 
were eliminated. The crude oil was diluted to the 
required dose, for either animal administration or the 
nanoemulsion formulation, by sunflower oil. 
Pharmaceutical formulation of lupine oil
The sunflower oil-diluted crude lupine oil 
(L) underwent emulsification with further particle 
size reduction to produce the nanoemulsion. Four 
nanoemulsion formulas (F1–F4) were prepared with 
different ratios, as mentioned previously, and in all 
cases, milky white nanoemulsions were obtained with 
no signs of phase separation. 
Effect of nanoemulsion composition on particle size 
The particle sizes of the four prepared nanoemulsions 
showed good correlations with the percentage of the oil 
phase, as shown in Table II. Increasing the oily phase 
from F1 to F4 resulted in increasing particle sizes 
from 261 nm to 373 nm, respectively. The particle size 
distribution analysis of the nanoemulsion formula F4 
displayed a polydispersity index (PDI) equal to 0.291, 
indicating good homogeneity (Figure 1A).
TABLE II - Particle size distribution analysis, viscosity, and 







F1 261 240 +ve
F2 305 469 +ve
F3 347 535 +ve
F4 373 659 -ve
FIGURE 1- Characterization of lupine oil nanoemulsion: (a) Droplet size distribution of the formula F4. (b) Photograph of 
different nanoemulsion preparations after 3 months storage at room temperature.
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Effect of nanoemulsion composition on viscosity 
Table II indicated that the viscosity of the prepared 
nanoemulsion was 240 cp, 469 cp, 535 cp, and 659 cp for 
formulations F1, F2, F3, and F4 respectively. 
Effect of storage on nanoemulsion phase separation
The prepared nanoemulsion formula F4 showed 
good stability; however, other formulations F1, F2, and 
F3 suffered from phase separation after being stored on 
a shelf for 3 months at room temperature (Figure 1B). 
According to the previously mentioned data, the F4 
nanoemulsion (NL) and the sunflower oil-diluted crude 
lupine oil (L) formulations were administered to the 
animals to investigate their physiological, biomedical, 
and hormone profiles.
Effect of lupine oil formulations on some 
physiological and biochemical parameters
The rats were divided into one of six groups; five 
of them were rendered obese by the administration of a 
HFD, and the remaining group served as the non-obese 
control. Both oil formulas (crude and nanoemulsion) 
were dispensed orally to the rats, and all results were 
taken in comparison with the untreated obese group 
(obese) unless otherwise specified.
Effect of lupine oil on liver enzymes 
To test the effect of lupine oil on liver integrity, 
the ALT level, which is one of the most important liver 
integrity enzymes, was ascertained. Administering the 
lupine oil did not significantly alter the ALT levels at any 
time point or for any formula (Table III). 
Effect of lupine oil on blood glucose and insulin levels
Table III showed a significant (P<0.05) effect of 
lupine oil nanoemulsion on fasting blood glucose and 
insulin levels in the (NL-20) group, although the level of 
both biomarkers increased, but not significantly so, by 
the induction of an obese state.
Effect of lupine oil on the lipid profile and epididymal fat
Feeding rats with a HFD for 7 weeks significantly 
(P<0.001) elevated their total cholesterol levels and 
decreased their HDL levels when compared with the 
non-obese control group (Table III). Administration 
of the crude lupine oil for 10 days (L-10) had no 
TABLE III - Physiological and biochemical parameters for the different groups and time points: none-obese (NO) obese untreated 
(obese), Lupine crude oil treated after 10 days (L-10) and 20 days (L-20), and lupine oil nanoemulsion formulation after 10 days 
(NL-10) and 20 days (NL-20). Values are mean ± SD (n = 5)
Parameters NO Obese L-10 NL-10 L-20 NL-20
ALT (U/L) 45.25 ± 4.11 47.25 ± 3.3 46 ± 2.71 50 ± 3.91 47.5 ± 4.8 49.25 ± 2.2
Fasting blood glucose (mg/dl) 86.75 ± 2.75 89.5 ± 6.45 83.25 ± 3.1 82.25 ± 4.34 81.5 ± 4.65 80.5 ± 3.1
Insulin (ng/ml) 1.39 ± 0.09 1.5 ± 0.07 1.34 ± 0.11 1.27 ± 0.08 1.29 ± 0.1 1.19 ± 0.02*
Total cholesterol (mmol/L) 2.77 ± 0.12*** 3.68 ± 0.09 3.52 ± 0.15 3.29 ± 0.09* 3.20 ± 0.11** 3.06 ± 0.11***
HDL-cholesterol (mmol/L) 1.52 ± 0.05*** 1.19 ± 0.07 1.22 ± 0.03 1.27 ± 0.07 1.37 ± 0.04* 1.42 ± 0.09**
Epididymal fat (gm) 1.9 ± 0.15*** 5.66 ± 0.86 5.32 ± 0.66 4.58 ± 0.63* 3.92 ± 0.65** 3.56 ± 0.51***
Body weight (gm) 219 ± 12.67*** 284.5 ± 17.15 274 ± 15.07 270 ± 9.41 257 ± 10.8 249.5 ± 10.53**
Food intake (gm) 101 ± 2.64 100 ± 1.00 93.3 ± 3.51 86 ± 5.29* 81.33 ± 3.2** 77.66 ± 6.8***
Notes: Abbreviations *P < 0.05, ** P < 0.01 and *** P < 0.001 compared with (Obese) values.
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significant effect on the level of total cholesterol; 
however, formulating the oil into a nanoemulsion 
(NL-10) significantly (P<0.05) reduced the level of 
total cholesterol in obese rats (Table III). Furthermore, 
administering both oil formulations (L-20 and NL-
20) for 20 days induced a significant (P<0.01 and 
P<0.001, respectively) reduction in total cholesterol 
levels in obese rats (Table III). Additionally, lupine oil 
significantly (P<0.05 and P<0.01) increased the levels 
of HDL-cholesterol after 20 days (L-20 and NL-20), 
respectively; however, no significant alterations were 
observed after 10 days of the oil administration. Table III 
indicates that there was a significant (P<0.001) increase 
in epididymal fat weight following administration 
of the HFD in comparison to the non-obese control 
group. This fat accumulation is significantly (P<0.05) 
reduced following the administration of the lupine oil 
nanoemulsion for 10 days, or after the administration 
of both oil formulations (L-20, P<0.01; and NL-20, P< 
0.001, respectively) for 20 days (Table III).
Effect of lupine oil on body weight and food 
intake in the HFD-induced obesity model
The HFD induced a significant (P<0.001) increase 
in the rats’ body weight when compared to the non-obese 
rats, although the amount of food intake in both groups 
was similar with no significant difference (Table III). 
After 10 days of lupine oil administration, no significant 
difference was detected in the rats’ body weight for 
either of the two oil formulations; however, the lupine 
oil nanoemulsion (NL-10) reduced the amount of food 
intake significantly (P<0.05) (Table III). After 20 days 
of the oil administration, the crude oil formulation (L-
20) still did not yield a significant change in the rats’ 
body weight; however, when the oil was formulated 
into the nanoemulsion (NL-20), a significant (P<0.01) 
reduction in the rats’ body weight was found. Both oil 
formulations (L-20 and NL-20) significantly reduced 
the amount of food intake by the obese rats (P<0.01 and 
P<0.001, respectively) (Table III).
Effect of lupine oil on rats’ hormone profile
Figure 2A shows a significant (P<0.01) increase 
in the leptin expression levels after 10 and 20 days 
of crude oil administration (L-10 and L-20) in the 
epididymal fat by 1.39±0.08-fold and 1.37±0.10-fold, 
respectively. This increase in leptin expression was 
amplified when the nanoemulsion formulations (NL-
10 and NL-20) were used to reach expression levels of 
1.73±0.14-fold and 1.92±0.12-fold, respectively. This 
noteworthy increase in leptin levels was not limited to 
the epididymal fat; rather, it extended to the serum level 
of the hormone as well, where a significant difference 
(P<0.05) can be observed in leptin expression level 
after 10 days of oil administration in the nanoemulsion 
formulation (Figure 2B). However, after 20 days of 
oil administration, both formulations were associated 
with a significant elevation of leptin expression with 
P-values <0.05 and <0.001, respectively (Figure 2B). 
In all cases, the nanoemulsion formulation showed 
a significant (P<0.001) increase in leptin expression 
levels when compared to the corresponding crude oil 
formulation (Figure 2).
A significant (P<0.01 and P<0.001) decrease in 
adiponectin levels in both epididymal fat and serum 
can be observed following the induction of obesity 
(Figure 3). The low adiponectin levels not only reverted 
back to the normal levels, but they were also elevated 
and exceeded the normal reading as well; this was the 
case for both the epididymal fat and serum following 
the administration of lupine oil. Western blot analysis 
revealed the over-expression of adiponectin in the 
epididymal fat following treatment with lupine oil 
by 1.7±0.15-fold, 3.8±0.133-fold, 5.1±0.42-fold, and 
9.6±1.52-fold in the L-10, NL-10, L-20, and NL-20 
groups, respectively (Figure 3A). Only the lupine oil 
nanoemulsion was able to cause a significant (P<0.05) 
increase in the adiponectin serum levels following 10 
days of administration; however, both formulations 
were able to induce the same effect after 20 days (Figure 
3B). Generally, the effect of the nanoemulsion was 
more pronounced and caused a nearly 10-fold increase 
in adiponectin levels in the epididymal fat after 20 days 
of formulation administration (Figure 3).
Western blot analysis was performed on both liver 
and epididymal fat homogenates to investigate the 
effect of lupine oil on AMPK expression. The analysis 
of epididymal fat AMPK levels revealed a sharp and 
significant (P<0.001) increase in the AMPK expression 
in all groups except L-10, which was nearly 15-fold 
greater following the administration of the lupine oil 
nanoemulsion formulation for 20 days (Figure 4A). 
Similarly, a significant over-expression of AMPK 
was detected in the liver homogenate following oil 
administration with P<0.001 for the NL-10, L-20, and 
NL-20 groups and P<0.01 for the L-10 group (Figure 
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FIGURE 2- Effect of lupine oil on leptin expression: (a) Leptin expression determined by Western blot analysis in the epididymal 
fat. (b) Serum level of leptin determined by ELISA. NO: non-obese group, Obese: obese untreated group, L-10 and L-20: 
crude lupine oil treated groups after 10 and 20 days, NL-10 and NL-20: Lupine oil nanoemulsion treated groups after 10 and 
20 days. Data are represented as means ± SD, (n = 5). * P < 0.05, ** P < 0.01 and *** P < 0.001 when compared with obese 
untreated values. # P < 0.05, ## P < 0.01 and ### P < 0.001 when crude oil preparation group is compared to its corresponding 
nanoemulsion formulation group (L-10 versus NL-10 and L-20 versus NL-20).
FIGURE 3- Effect of lupine oil on adiponectin expression: (a) adiponectin expression determined by Western blot analysis in 
the epididymal fat. (b) Serum level of adiponectin determined by ELISA. NO: non-obese group, Obese: obese untreated group, 
L-10 and L-20: crude lupine oil treated groups after 10 and 20 days, NL-10 and NL-20: Lupine oil nanoemulsion treated groups 
after 10 and 20 days. Data are represented as means ± SD, (n = 5). * P < 0.05, ** P < 0.01 and *** P < 0.001 when compared 
with obese untreated values. # P < 0.05, ## P < 0.01 and ### P < 0.001 when crude oil preparation group is compared to its 
corresponding nanoemulsion formulation group (L-10 versus NL-10 and L-20 versus NL-20).
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4B). Comparable to what was observed for leptin and 
adiponectin, the lupine oil nanoemulsion formulation 
(NL-10 and NL-20) showed more intense activation 
for AMPK following administration for either 10 days 
or 20 days (Figure 4).
The consumption of excess nutrients with high 
caloric values is responsible for the widespread obesity in 
developing countries and around the world. Many common 
metabolic complications are primarily ascribed to obesity, 
including dyslipidemia, insulin resistance, diabetes, and 
hypertension (Deng, Scherer, 2010). Anti-obesity drugs 
are important adjunctive therapy, in combination with 
lifestyle changes, to improve the obesity status of obese 
individuals. Unfortunately, many of the reported anti-
obesity drugs are associated with many limitation due to 
their high attrition rates, their burden on the liver, and the 
lack of long-term morbidity and mortality data (Padwal, 
Majumdar, 2007). In light of the aforementioned data 
on the obesity pandemic, the development of safe and 
effective treatment alternatives should be a priority. This 
study investigates lupine oil as an anti-obesity drug, which 
is in accordance with the line of alternative developments 
of natural and safe weight-loss agents.
In the present study, the effect of different 
formulations of lupine oil on HFD-induced obesity was 
investigated. Treatment with lupine oil significantly 
decreased rats’ food intake, epididymal fat, and body 
weight, and improved their lipid profile levels; it also 
modulated the rats’ blood glucose levels and insulin 
resistance. This anti-obesity effect of lupine oil was 
associated with the increased expression of both 
adiponectin and leptin, and this effect may be mediated 
through AMPK activation. Additionally, the oil and 
its formulations did not have any effects on the liver’s 
integrity, as was proven by the non-altered ALT levels.
Obesity is characterized by dyslipidemia and the 
accumulation of fat in the abdominal region. Table III 
illustrates that there was a reduction in the rats’ body 
weight and epididymal fat weight. This reduction is 
associated with reduced food intake, and it may be 
influenced by the rats’ decreased appetite for food 
intake. This could be attributed to increased levels of 
lipolysis by the administration of lupine oil. Oleic acid 
is the primary fatty acid component in lupine seed oil 
(40%–50%), followed by linoleic acid (8%–16%) and 
α-linolenic acid (5%–10%) (Sbihi et al., 2013). Oleic 
acid was proven to have an anorectic effect, which is 
independent of leptin (Obici et al., 2002). Moreover, 
α-linolenic is evidenced to have an inhibitory effect on 
lipogenesis and thus exhibits hypolipidemic activity (Su 
FIGURE 4- Effect of lupine oil on AMPK expression: (a) Expression of AMPK in epididymal fat determined by Western blot 
analysis. (b) Expression of AMPK in liver homogenate determined by Western blot analysis. NO: non-obese group, Obese: 
obese untreated group, L-10 and L-20: crude lupine oil treated groups after 10 and 20 days, NL-10 and NL-20: Lupine oil 
nanoemulsion treated groups after 10 and 20 days. Data are represented as means ± SD, (n = 5). * P < 0.05, ** P < 0.01 and *** P 
< 0.001 when compared with obese untreated values. # P < 0.05, ## P < 0.01 and ### P < 0.001 when crude oil preparation group 
is compared to its corresponding nanoemulsion formulation group (N-10 versus NL-10 and L-20 versus NL-20). DISCUSSION
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et al., 2016). Lupine seeds are known to reduce food 
intake by 30%, as they decrease appetite; however, this 
effect has been attributed to the protein and carbohydrate 
parts of the seed (Belski et al., 2011). Nevertheless, this 
study suggests that lupine seed oil plays this role. Lupine 
oil significantly reduced the total cholesterol levels and 
increased the HDL levels in a time- and formulation-
dependent manner. This may be attributed to gene 
expression regulation, particularly among those genes 
involved in lipid metabolism; however, this speculation 
requires further investigation.
Leptin and adiponectin are adipocyte hormones 
that control energy homeostasis (Havel, 2002). Leptin, a 
pleiotropic hormone, plays a role in appetite suppression 
and it increases energy expenditure (Mantzoros et 
al., 2011). It acts as a signal of the body’s nutritional 
status to the reproductive, immune, cardiovascular, 
skeletal, and thyroid systems. Moreover, it plays a 
regulatory role in blood sugar levels through its effects 
on the liver, pancreas, and blood pressure, both directly 
and via the sympathetic nervous system (Nasrallah, 
Ziyadeh, 2013). The present study showed that lupine 
oil not only maintained the elevations in serum leptin 
necessary for decreasing rats’ appetite for food intake, 
but the oil also increased the expression of leptin in 
the epididymal fat. The increased level of leptin has a 
direct effect on the hypothalamus, which reduces one’s 
appetite and subsequently decreases food intake; this 
may explain the reduction in body weight observed in 
the present study. 
Leptin and adiponectin tend to normalize insulin 
action through AMPK-induced fat oxidation, leading 
to reduced triglyceride content intramyocellulary 
and in the liver (Meier, Gressner, 2004; Galic, 
Oakhill, Steinberg, 2010). Adiponectin has been 
linked to glucose, lipid, and cardiovascular regulation 
(Ahima, 2006; Akingbemi, 2013). A deficiency of 
adiponectin and/or decreased adiponectin receptor-
mediated activity contribute to insulin resistance, 
hyperinsulinemia (Meier, Gressner, 2004), liver 
disease, and coronary heart disease (Akingbemi, 
2013). Adiponectin has an insulin-sensitizing effect, 
and it also exerts its effects on metabolism of the 
lipid profile (Lara-Castro et al., 2007). Adiponectin 
is an attractive therapeutic target for the prevention 
of cardiovascular diseases and diabetes, as it can be 
significantly increased by diet, exercise, and weight 
loss (Silva, de Almeida, Feoli, 2011). The elevation of 
adiponectin levels led to increased insulin sensitivity, 
enhanced fatty acid oxidation, and increased energy 
expenditure, and it also reduced the production of 
glucose by the liver (Galic, Oakhill, Steinberg, 2010). 
The results clearly show the reduced expression of 
adiponectin in the untreated obese group; moreover, 
the lupine oil can induce over-expression of the 
hormone in the epididymal fat, as well as in the serum, 
at all time points and, in part, with all formulations. 
This elevation in adiponectin level may explain the 
reduced blood glucose and insulin levels, as well as the 
ameliorated lipid profile. Diets containing α-linolenic 
or oleic fatty acids, which are the main components 
of lupine oil, improved the state of insulin resistance 
in obese mice (Oliveira et al., 2015); the present study 
may explain the mechanism of such improvement 
through the over-expression of adiponectin in both 
epididymal fat and serum.
Activated AMPK, through high levels of 
adiponectin, stimulates fatty acid oxidation, 
mitochondrial biogenesis, and glycolysis, and it also 
inhibits glycogen, fatty acid, and protein synthesis and 
gluconeogenesis; it also has a direct appetite-regulating 
effect in the hypothalamus (Lim, Kola, Korbonits, 
2010). The results of this study indicated that lupine oil 
increased the expression of both leptin and adiponectin, 
and this was concomitant with the over-expression of 
AMPK in both the epididymal fat (at some points, to 
about 20-fold) and liver, implying that lupine oil activity 
is associated with the AMPK pathway.
Numerous lipophilic drugs demonstrate low oral 
bioavailability due to their poor aqueous solubility 
(Gershanik, Benita, 2000). Lupine oil has a lipophilic 
character and it may be hindered by its low bioavailability 
due to its interrupted absorption. Nanoemulsions are 
submicron-sized dosage forms that area associated 
with various advantages, including their enhanced drug 
solubility and bioavailability, increased drug loading, 
and controlled drug release (Choi et al., 2010; Sharma et 
al., 2013). Accordingly, lupine oil was formulated into 
a nanoemulsion to overcome any absorption limitations 
and to ensure enhanced oil bioavailability. The results 
stated that nanoemulsion formulations with particle 
sizes <400 nm were obtained and exhibited good 
viscosities, which will not affect the stability or oral 
administration aptitude of the prepared formulation. 
As the oil phase concentration increases, the viscosity 
of the prepared nanoemulsion increases (Table II), and 
these results are in accordance with those reported 
previously (Dłużewska, Stabiecka, Maszewska, 2006). 
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Nanoemulsion formulation F4 showed good stability 
over 3 months at room temperature, so it was selected 
for further in vivo investigations in comparison to 
crude lupine oil. The administration of the lupine oil 
nanoemulsion formulation intensified the physiological, 
biochemical, and hormonal activity of the oil in 
all cases and at all time points. The nanoemulsion 
formulation of the oil showed a significant difference 
in the efficacy of the lupine oil, especially in terms of 
adiponectin and AMPK levels. In addition to the fact 
that the nanoemulsion formulation increased the lupine 
oil’s bioavailability, this preparation can also be used 
as a lipid-based formula that can reduce the limitations 
associated with the slow and incomplete dissolution of 
those drugs that are poorly soluble in water; moreover, 
this preparation can also facilitate the creation of 
solubilized phases from which absorption may occur 
(Humberstone, Charman, 1997). This formula can 
especially be implemented for those drugs that can be 
used to counteract obesity, diabetes, and hyperlipidemia, 
so as to take advantage of the synergistic activity 
between the drug and the formulated lupine oil.
In the presented study, lupine oil showed an anti-
obesity effect when administered to the HFD-induced 
obese rats. The oil was able to ameliorate the alterations 
in the lipid profile caused by the HFD, and it improved 
both insulin and blood sugar levels as an indication of 
reduced insulin resistance. Notably, lupine oil reduced 
both the epididymal fat weight and food intake, which 
are considered challenges for obese patients. The use of 
lupine oil was found to be safe, as it did not place any 
burden on the liver; this is in contrast to many other 
anti-obesity drugs, which are all associated with hepatic 
problems. Lupine oil enhanced leptin and adiponectin 
levels in both the serum and epididymal fat, and it also 
activated AMPK in both the epididymal fat and liver. 
The formulation of lupine oil into the nanoemulsion 
enhanced its activity across all the aforementioned 
biomarkers, particularly the hormones, indicating that 
there was enhanced absorption and bioavailability of 
the formulated oil.
The authors of this study recommend the use of 
a lupine oil nanoemulsion as a potential anti-obesity 
agent against diet-induced obesity, which can enhance 
energy expenditure and reduce appetite, epididymal 
fat, and body weight without affecting the liver. This 
recommendation requires further investigations using 
clinical models to confirm the medicinal properties of 
this preparation on humans.
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